Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific, Middle East and Africa: 2,207 cases from 44 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by authority- Korea Fair Trade Commission (KFTC) €1.9m 100 % · 1 case
What for?
by area of lawAll areas of law
Who?
by company- Anonymised companies €1.9m 100 % · 1 case
When?
per year, by date of decision| Period | Cases | Total |
|---|---|---|
| 2022 | 1 | €1.9m |
| 2023 | 0 | – |
| 2024 | 0 | – |
| 2025 | 0 | – |
| 2026 | 0 | – |
1 case
13 Oct 2022 five pharmaceutical companiesPay-for-delay in cancer drugs: KFTC sanctions originator and generic manufacturers €1.9m
The Korea Fair Trade Commission (KFTC, Korea's competition authority) objected to an agreement concluded at the end of September 2016 under which the generics side undertook not to manufacture or launch generic versions of three cancer drugs in Korea from October 2016 to December 2020, receiving in return exclusive distribution rights for these originator products from the originator side; according to the KFTC, the arrangement was terminated early on 12 January 2018. It issued cease-and-desist orders against all five companies (two on the originator side, including its Korean company, and three on the generics side, including its Korean company) and provisionally set fines totalling KRW 2,645 million: KRW 1,146 million for the originator side and KRW 1,499 million for the generics side.
Distribution or licensing agreements with a potential generic manufacturer must not contain a clause that rules out its own market entry.
Agreements with potential competitors to refrain from market entry (pay-for-delay)
- Authority / court
- Korea Fair Trade Commission (KFTC)
- Area of law
- Competition law · Cartels and collusion
- Legal basis
- Art. 19 Abs. 1 Nr. 3 MRFTA a. F. (Monopoly Regulation and Fair Trade Act; heute Art. 40 Abs. 1 Nr. 3)
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Published
- 13 Oct 2022
Original amount 2,645,000,000 KRW, converted at the ECB reference rate of 13 Oct 2022.
- Korea Fair Trade Commission (KFTC), Veröffentlichung der Behörde (Entscheidung 2022) Decision of an authority
Checked against the official source on 8 Oct 2026 · Company name anonymised since 13 Oct 2024 · Direct link